MTHFD2 and cancer: Although MTX and VE-821 significantly blocked DNA RF progression in both cancer and nontumorigenic cells, MTHFD2 inhibitors effectively impaired DNA replication only in AML cells, sparing nontumorigenic lymphocytes (Fig. 4f).